Yeast as carrier for drug delivery and vaccine construction

Tan, Yifu; Chen, Liwei; Li, Ké; Lou, Beibei; Liu, Yanfei; Liu, Zhenbao

doi:10.1016/j.jconrel.2022.04.032

Cited by 35 publications

(19 citation statements)

References 219 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, they amplify the range of administration methods for intranasal, oral, and intravaginal mucosal routes [176]. Some of these organisms are used as immunological adjuvants and food additives and have certification and recognition as safe (GRAS) by the FDA [178,179]. They can be heat-inactivated or modified to ensure host safety to delete their pathogenic components [176,178].…”

Section: Microorganism-based Delivery Systemsmentioning

confidence: 99%

“…Yeasts are versatile single-celled microorganisms commonly used in the food industry that have potential application value as biofactories of therapeutic proteins and carriers of biological molecules [179]. Some strains have been certified as generally recognized as safe (GRAS) by the FDA and have been used for bioproduction [192].…”

Section: Yeastsmentioning

confidence: 99%

“…Their adjuvant activity is obtained by the various components that can stimulate or modulate the host immune response [193]. The cell wall mainly comprises β-1,3 and β-1,6-glucan, chitin, mannan, and other polysaccharides [179]. These promote immunostimulation by binding with dectin receptors, mannose-fucose, and Toll-like receptors (TLRs) such as TLR-2, 4, and 6 in DCs [138].…”

Section: Yeastsmentioning

confidence: 99%

“…However, although yeast release transporters show great potential, there is still a need to research and understand their observed advantages, as well as a better evaluation of the amount of genetic material to be carried, specific uptake in the body, and their transport in vivo [179].…”

Section: Yeastsmentioning

confidence: 99%

See 3 more Smart Citations

Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

et al. 2022

View full text Add to dashboard Cite

Prophylactic vaccines against human papillomavirus (HPV) have proven efficacy in those who have not been infected by the virus. However, they do not benefit patients with established tumors. Therefore, the development of therapeutic options for HPV-related malignancies is critical. Third-generation vaccines based on nucleic acids are fast and simple approaches to eliciting adaptive immune responses. However, techniques to boost immunogenicity, reduce degradation, and facilitate their capture by immune cells are frequently required. One option to overcome this constraint is to employ delivery systems that allow selective antigen absorption and help modulate the immune response. This review aimed to discuss the influence of these different systems on the response generated by nucleic acid vaccines. The results indicate that delivery systems based on lipids, polymers, and microorganisms such as yeasts can be used to ensure the stability and transport of nucleic acid vaccines to their respective protein synthesis compartments. Thus, in view of the limitations of nucleic acid-based vaccines, it is important to consider the type of delivery system to be used—due to its impact on the immune response and desired final effect.

show abstract

Section: Microorganism-based Delivery Systemsmentioning

confidence: 99%

Section: Yeastsmentioning

confidence: 99%

Section: Yeastsmentioning

confidence: 99%

Section: Yeastsmentioning

confidence: 99%

See 2 more Smart Citations

Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Yeast is another potential alternative, but the use of this source as a drug delivery system lies in the early stages compared to those. More information about yeast for drug delivery application can be found in Tan et al work [ 20 ].…”

Section: Natural Membrane Sourcesmentioning

confidence: 99%

Biomimetic Nanovesicles—Sources, Design, Production Methods, and Applications

et al. 2022

View full text Add to dashboard Cite

Despite all the progress in the field of liposomes and nanoparticles for applications as drug and gene delivery systems, the specific targeting and immune system escape capabilities of these systems are still limited. Biomimetic nanovesicles emerged as a strategy to overcome these and other limitations associated with synthetic carriers, such as short circulation time, cytotoxicity, and difficulty in crossing biological barriers, since many of the desirable abilities of drug delivery systems are innate characteristics of biological vesicles. Thus, the question arises: would biomimetic nanovesicles be responsible for addressing these advances? It is currently known that biomimetic nanovesicles (BNV) can combine the intrinsic advantages of natural materials with the well-known production methods and controllability of synthetic systems. Besides, the development of the biotechnology and nanotechnology fields has provided a better understanding of the functionalities of biological vesicles and the means for the design and production of biomimetic nanovesicles (BNV). Based on this, this work will focus on tracking the main research on biomimetic nanovesicles (BNV) applied as drug and gene delivery systems, and for vaccines applications. In addition, it will describe the different sources of natural vesicles, the technical perspectives on obtaining them, and the possibility of their hybridization with synthetic liposomes.

show abstract

Engineered Living Materials for Advanced Diseases Therapy

Duan

Pan

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Natural living materials serving as biotherapeutics exhibit great potential for treating various diseases owing their immunoactivity, tissue targeting, and other biological activities. In this review, we summarize the recent developments in engineered living materials, including mammalian cells, bacteria, viruses, fungi, microalgae, plants, and their active derivatives that have been used for treating various diseases. Further, the future perspectives and challenges of such engineered living material‐based biotherapeutics are discussed to provide considerations for future advances in biomedical applications.This article is protected by copyright. All rights reserved

show abstract

Yeast as carrier for drug delivery and vaccine construction

Cited by 35 publications

References 219 publications

Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

Biomimetic Nanovesicles—Sources, Design, Production Methods, and Applications

Engineered Living Materials for Advanced Diseases Therapy

Contact Info

Product

Resources

About